Bunkerhill MAC vs iPredict Eye Screening
AI Verdict
Choose Bunkerhill MAC if…
Choose Bunkerhill MAC if your cardiology or radiology department aims to proactively identify patients at increased cardiovascular risk by leveraging existing, routine chest CT scans for mitral annular calcification (MAC). This tool is ideal for integrating MAC detection and quantification into automated workflows for follow-up and care coordination within your EHR and clinical systems.
View Bunkerhill MAC →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your primary care practice or ophthalmology clinic requires a versatile, AI-powered solution for early detection of multiple retinal diseases like AMD, DR, and Glaucoma. This tool is particularly well-suited for settings that benefit from quick, non-invasive screening, telemedicine integration, and an additional layer of systemic disease risk prediction for conditions like stroke and heart attack.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Bunkerhill MAC | iPredict Eye Screening |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Cloud-based, integrates with EHRs. | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B, iPredict Eye Screening, emphasizes ease of operation with an advanced touchscreen interface, non-invasiveness, and rapid results (test in <5 minutes, report in <60 seconds). This suggests a strong focus on a user-friendly experience at the point of care. While Tool A integrates seamlessly with existing systems, Tool B's description highlights direct user interaction and efficiency.
Clinical Value
iPredict Eye ScreeningTool B, iPredict Eye Screening, offers a broader clinical scope by screening for multiple conditions (Diabetic Retinopathy, AMD, Glaucoma) and providing risk prediction for systemic diseases like stroke and heart attack. It also provides specific accuracy metrics (e.g., AMD sensitivity 86.86%, specificity 94.13%). Tool A focuses on a single, albeit important, condition (MAC).
Pricing & Value
iPredict Eye ScreeningTool B, iPredict Eye Screening, provides a transparent pricing model, specifying a 'per patient screening on a Software as a Service (SaaS) model' with an estimated cost of '$10-$20 per patient'. This allows potential buyers to better understand and assess the value proposition. Tool A only states 'contact for pricing', offering no immediate transparency.
Enterprise Readiness
iPredict Eye ScreeningBoth tools are FDA-cleared, cloud-based, and integrate with EHRs. However, Tool B explicitly states it is HIPAA compliant, indicated by 'hipaa_compliant: 1'. Tool A states HIPAA compliance as 'likely, but not explicitly stated', giving Tool B a slight edge in explicitly declared enterprise readiness regarding compliance.
Innovation
Bunkerhill MACTool A, Bunkerhill MAC, explicitly highlights its use of 'Generative AI for clinical reasoning and action' and integration with the 'Carebricks generative AI platform'. This suggests a potentially more advanced and innovative application of AI beyond just detection, focusing on higher-level clinical intelligence. While Tool B is innovative in its multi-disease screening and telemedicine integration, it doesn't specify the same advanced AI paradigm.
Support & Docs
TieNeither the provided structured facts nor a general web search for 'Bunkerhill Health support documentation' or 'iHealthScreen support documentation' yielded specific details regarding dedicated support channels, service level agreements (SLAs), or comprehensive public documentation portals for either product. Therefore, it is not possible to distinguish between the two on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Bunkerhill MAC | iPredict Eye Screening |
|---|---|---|
| Product Name | Bunkerhill MAC | iPredict Eye Screening |
| Company | Bunkerhill Health | iHealthScreen |
| Primary AI Detection Focus | Detects and quantifies mitral annular calcification (MAC) on routine CT scans. | AI-powered screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma; also provides risk prediction for systemic diseases like stroke and heart attack. |
| Integration | Integrates with existing EHRs and clinical systems via Carebricks platform. | Integrates with EHR and telemedicine services. |
| Key Specialties | Cardiology, Radiology | Family Medicine, Internal Medicine, Ophthalmology |
| Input Modality / Target Population | Routine, non-gated chest CT scans for cardiovascular risk identification. | Retinal images for patients aged 50 years and older (AMD), and general screening for DR and Glaucoma. |
Videos
Demos, reviews, and walkthroughs featuring Bunkerhill MAC and iPredict Eye Screening.